Healthcare sector | Diagnostics & Research industry
| Price | $11.68 |
|---|---|
| Shares Outstanding | 129.39M |
| Net Current Assets / Share | $-1.19 |
| Net Tangible Assets / Share | $0.15 |
| Max Earning Power / Share | $-0.69 |
| Adjusted Earning Power |
$-2.0
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
1.09%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Ave Max Earning Power (5Y) | $0.86 |
| Ave Max Earning Power (5Q Annualized) | $0.32 |
| Ave Max Earning Power Delta (5Q Ann - 5Y) | $-0.54 |
| Net Cash / Share | $0 |
| Dividend indicators | Value | Date |
|---|---|---|
| Pays Dividend | No | 12-19-2025 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 12-19-2025 |
| Net Income Positive | No | 12-19-2025 |
| Avg CA Burn (Annual %) | -4.71% | 12-19-2025 |
| Avg CA Burn (Quarterly %) | -12.93% | 12-19-2025 |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2025-10-30 | 129,387,801 | +209,179 |
| 2025-09-17 | 129,178,622 | -378 |
| 2025-07-31 | 129,179,000 | +484,000 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.